Datum Källa Rubrik Typ Alternativ
2021-05-05 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) den 5 maj 2021 Pressreleaser Ladda ner | Visa Stäng
2021-05-05 Enzymatica Bulletin from Annual General Meeting of Enzymatica AB (publ) on 5 May 2021 Pressreleaser Ladda ner | Visa Stäng
2021-05-05 Enzymatica Enzymatica AB: BioStock: Enzymaticas Q1-rapport visar att pandemin drabbar försäljningen Pressreleaser Visa Stäng
2021-04-29 Enzymatica Enzymatica AB: Lägre försäljning till följd av pandemin men nyemission säkerställer fortsatt internationell expansion Rapporter Ladda ner | Visa Stäng
2021-04-29 Enzymatica Enzymatica AB: Lower sales due to the pandemic but new rights issue secures continued international expansion Rapporter Ladda ner | Visa Stäng
2021-04-22 Enzymatica Enzymatica AB: BioStock: Enzymaticas styrelseordförande om nyemissionen Pressreleaser Visa Stäng
2021-03-31 Enzymatica Enzymatica AB: Enzymatica Publication of the Annual Report 2020 Rapporter Ladda ner | Visa Stäng
2021-03-31 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2020 Rapporter Ladda ner | Visa Stäng
2021-03-31 Enzymatica Kallelse till årsstämma 2021 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-31 Enzymatica Notice of Annual General Meeting 2021 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 31 Mar 2021 | Enzymatica

Notice of Annual General Meeting 2021 in Enzymatica AB (publ)

The shareholders in Enzymatica AB (publ), reg. no. 556719-9244 (the ”Company”), are hereby given notice that the annual general meeting will be held on 5 May 2021.

In order to prevent the spread of the virus causing covid-19, the board of directors has decided that the annual general meeting shall be held without the physical presence of shareholders, proxies or external parties and that the shareholders shall have the opportunity to vote only by mail prior to the general meeting.

Information on the resolutions passed by shareholders will be disclosed on 5 May 2021, as soon as the outcome of the postal voting has been finally confirmed.

Notification etc.
Those who wish to participate in the annual general meeting must:

i. be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of 27 April 2021; and
ii. give notice of intent to participate no later than 4 May 2021, by casting their postal vote in accordance with the instructions under the heading ”Postal voting” below, so that the postal voting form is received by the Company no later than that day.

In order to be entitled to participate in the meeting, a shareholder whose shares are registered in the name of a nominee must, in addition to giving notice of participation in the annual general meeting, register its shares in its own name at Euroclear Sweden AB so that the shareholder is listed in the share register as of the record date of 27 April 2021. Such re-registration may be temporary (so called voting rights registration), and a request for such voting rights registration shall be made to the nominee, in accordance with the nominee’s routines, at such time in advance as decided by the nominee. Voting rights registration that has been made by the nominee no later than 29 April 2021, will be taken into account in the presentation of the share register.

Postal voting
The board of directors has decided that shareholders should be able to exercise their voting rights only by postal voting in accordance with section 22 of the Act (2020:198) on Temporary Exceptions to Facilitate the Execution of General Meetings in Companies and Other Associations. A special form must be used for the postal vote. The form for postal voting is available on the Company’s website www.enzymatica.se and at the Company’s head office, Ideon Science Park in Lund. Completed and signed forms for postal voting can be sent by mail to Enzymatica AB (publ), Ideon Science Park, Scheelevägen 19, 223 70 Lund (mark the envelope ”Postal voting AGM 2021”) or by email to louise.forssell@enzymatica.com.Completed forms must be received by the Company no later than 4 May 2021.

The shareholders may not provide special instructions or conditions to the postal vote. If so, the entire postal vote is invalid. Further instructions and conditions can be found in the postal voting form.

Proxies etc.
Shareholders who are casting postal votes via proxy should submit a power of attorney, dated and signed by the shareholder, together with the postal vote. Power of attorney forms are available on the Company’s website, www.enzymatica.se, and at the Company’s head office, Ideon Science Park in Lund. If the shareholder is a legal person, a certificate of registration or other documents of authority shall be attached to the form.

Proposed agenda

1. Opening of the meeting.
2. Election of chairman of the meeting.
3. Election of persons to approve the minutes.
4. Preparation and approval of the voting list.
5. Approval of the agenda.
6. Determination as to whether the meeting has been duly convened.
7. Presentation of the annual report and auditor’s report and the consolidated annual report and consolidated auditor’s report.
8. Resolution on:
a. Adoption of the profit and loss statement and balance sheet, as well as the consolidated profit and loss statement and the consolidated balance sheet.
b. Distribution of the Company’s profit or loss according to the adopted balance sheet.
c. Discharge from liability of the members of the board of directors and the CEO.
9. Determination of the number of members of the board of directors and auditors.
10. Determination of remuneration to the members of the board of directors and the auditors.
11. Election of:
a. Members of the board of directors and deputy directors.
b. Chairman of the board of directors.
c. Auditors and any deputy auditors.
12. Resolution on implementation of an incentive program for senior executives and key personnel by way of (A) directed issue of warrants; and (B) approval of transfer of warrants.
13. Resolution regarding authorisation of the board of directors to issue new shares.
14. Resolution on amendments to the articles of association.
15. Closing of the meeting.

Resolution proposals
Item 2 – Resolution on election of chairman of the meeting
The nomination committee proposes that attorney Henric Stråth, Moll Wendén Law Firm, shall be elected chairman of the meeting.

Item 3 – Resolution on election of persons to approve the minutes
Stefan Hansson, or the person appointed by the board of directors if he has an impediment to attend, is proposed to be elected to approve the minutes of the annual general meeting together with the chairman. The task of approving the minutes of the annual general meeting also includes verifying the voting list and that the advanced votes received are correct stated in the minutes of the annual general meeting.

Item 4 – Preparation and approval of the voting list
The voting list proposed to be approved is the voting list prepared by the Company, based on the general meeting share register and received postal votes, controlled and checked by the persons assigned to approve the minutes.

Item 8(b) – Resolution on disposition of the Company’s profit or loss
The board of directors has proposed that no dividend is paid for the financial year 2020 and that the Company’s funds available for distribution, including the loss of the year, is carried forward.

Items 9-11 – Resolution on election of members of the board of directors and auditor and remuneration
As resolved at the annual general meeting of 2019, the nomination committee shall consist of the chairman of the board of directors together with a representative of each of the four largest shareholders by votes at the end of September each year. Consequently, the nomination committee consists of the nomination committee’s chairman Håkan Roos through Roosgruppen AB, Mats Andersson through Abanico Invest AB and several other companies as well as private holdings, Björn Algkvist through Fibonacci Asset Management AB, Guðmundur Pálmason through Fortus hf., and the chairman of the board of directors, Bengt Baron.

Proposal pursuant to item 9: The nomination committee proposes that the board of directors shall consist of six (6) ordinary members without deputies until the end of the next annual general meeting. Furthermore, the nomination committee proposes that a registered auditing company is appointed as auditor until the end of the next annual general meeting. 

Proposal pursuant to 10: The nomination committee proposes that remuneration for the board of directors, excluding remuneration for committee work, shall be paid with a total of SEK 1,625,000 (previously SEK 1,275,000) of which SEK 500,000 (previously SEK 400,000) is remuneration for the chairman of the board of directors and SEK 225,000 (previously SEK 175,000) to every other member of the board of directors who are not employed by the Company. In addition, the nomination committee proposes that remuneration for work in the audit committee shall be paid with SEK 175,000 (previously SEK 100,000) to the chairman of the audit committee and SEK 50,000 (previously SEK 50,000) to every other member. Further, it is proposed that no remuneration shall be paid for work in the remuneration committee.

The nomination committee proposes that remuneration to the auditor shall be paid in accordance with approved invoices. 

Proposal pursuant to item 11: The nomination committee proposes the re-election of Bengt Baron, Guðmundur Pálmason, Mats Andersson, Louise Nicolin and Fredrik Lindberg as well as the election of Helene Willberg as ordinary members. Marianne Dicander Alexandersson has denied re-election. Furthermore, it is proposed that Bengt Baron is re-elected as chairman of the board.

Information on members proposed for election is available on the Company’s website, www.enzymatica.se

In accordance with the audit committee’s recommendation, the nomination committee proposes re-election of the registered auditing company Deloitte AB. Deloitte AB has notified that, should the annual general meeting approve the proposal, the authorised public accountant Jeanette Roosberg will be the auditor-in-charge.

Item 12 – Resolution on implementation of an incentive program for senior executives and key personnel by way of (A) directed issue of warrants; and (B) approval of transfer of warrants
The board of directors proposes that the annual general meeting resolves to implement an incentive program for senior executives and key personnel in the group based on issue and transfer of warrants (the ”Warrants Program 2021/2024”), on the following terms and conditions:

A. The board’s proposal for directed issue of warrants

A maximum of 1,000,000 warrants shall be issued for the Warrants Program 2021/2024.

With deviation from the shareholders’ preferential rights, the right to subscribe shall vest in the Company’s wholly owned subsidiary, Enzymatica Care AB, reg. no. 556701-7495 (the ”Subsidiary”). The reason for the deviation from the shareholders’ preferential rights is that the warrants shall be used within the Warrants Program 2021/2024.

Subscription of the warrants shall be made on a designated subscription list at the latest within six months from the issue resolution. Over subscription cannot occur.

The warrants shall be issued to the Subsidiary against cash consideration corresponding to the warrant’s market value calculated in accordance with the Black Scholes formula. The calculation of the market value of the warrants shall be established by Öhrlings PricewaterhouseCoopers AB in connection with the expiration of the measurement period on 19 May 2021. Payment shall be made in connection with subscription.

Each warrant shall entitle to subscription of one (1) share in the Company. Subscription of shares by virtue of the warrants may be effected during the period as from 15 May 2024 up to and including 30 September 2024.

The subscription price per share shall correspond to 150 per cent of the volume weighted average price according to Nasdaq First North Growth Market’s official price list for shares in the Company during the period as from and including 6 May 2021 to and including 19 May 2021. The subscription price and the number of shares that each warrant entitles right to subscribe for may be subject to customary recalculation in the event of split-up or consolidation of shares, rights issues and similar events.

The shares issued upon utilisation of a warrant shall confer right to dividends as from the first record date for dividends that occurs immediately following effectuation of subscription to such extent that the share has been recorded in the Company’s share ledger as interim share.

In case all warrants are utilised for subscription of new shares, the share capital will increase with SEK 40,000.02.

B. The board’s proposal for transfer of warrants

The Warrants Program 2021/2024 shall principally be carried out in accordance with what is stated below.

The Subsidiary shall have the right, on one or several occasions, to transfer the warrants to employees and consultants in the Company, or a Company within the group in which the Company is the parent Company, in accordance with the terms and guidelines set forth below. Transfer to participants under the Warrants Program 2021/2024 shall be made against cash consideration which shall correspond to the market value of the warrant calculated in accordance with the above.

The board of directors of the Company shall resolve upon allotment of warrants, which shall be made in accordance with the following allocation, whereby it is noted that the distribution of warrants can differ between the participants in the respective category:

Position Number of warrants
CEO A maximum of 500,000
The Company’s Director of A maximum of 200,000 per person
Operations and Commercial
Director
Other employees/consultants A maximum of 20,000 per person
(for now 5 persons)

First allotment is scheduled to made in May 2021.

The participants can subscribe for a lower number of warrants compared to what is offered to the participants. Over subscription cannot occur.

The warrants that may remain after the first allotment may be allotted to future employees and consultants in the Company, or a Company within the group in which the Company is the parent Company, or to such employees that have been promoted, at the market value at each given time in accordance with the allocation principles stated above, whereby the above-mentioned number of employees and consultants in the respective category may change. Transfer of warrants may not take place after the annual general meeting 2022.

Right to allotment in the Warrants Program 2021/2024 requires that the participant, at the time of allotment at the latest, holds a position in the Company or has signed an agreement regarding it, and has not, at such time, informed or been informed of that the employment or assignment will be terminated. The Company shall, in connection with allotment and as long as it does not entail negative tax consequences for the Company or the participant, have the right to repurchase warrants if the participant’s employment or assignment in the group ends or if the participant in turn wishes to transfer the warrants.

For participants in other jurisdictions than Sweden, it is implied that transfer of warrants is legally possible and that transfer, in the board of directors’ opinion, can be carried out with reasonable administrative and financial efforts at their established market value. The board of directors shall be authorised to adjust the terms and conditions of the Warrants Program 2021/2024 to the extent required in order for allotment and exercise of warrants to participants in other jurisdictions, to the extent practically possible, to be carried out under the same conditions imposed by the Warrants Program 2021/2024.

Other information regarding the Warrants Program 2021/2024

The reasons for the implementation of the Warrants Program 2021/2024 and the deviation from the shareholders’ preferential rights is that the board of directors considers that a warrant program that gives senior executives and key personnel the opportunity to take part in the Company’s long-term performance promotes participation and responsibility and provides increased motivation and loyalty to work for a favorable economic development in the Company. An incentive program is also expected to contribute to the opportunities to recruit and retain competent, motivated and engaged co-workers as well as to the fulfillment of the Company’s business strategy, long-term interests and sustainability.

Since the warrants in the Warrants Program 2021/2024 are transferred at market value, the Company’s assessment is that the Company will not incur any social costs due to Warrants Program 2021/2024. Hence, the costs related to Warrants Program 2021/2024 will only be composed of limited costs for implementation and administration of the program. Otherwise, the Warrants Program 2021/2024 is not expected to entail any costs of significance for the Company, and for this reason no measures to hedge the program have been taken.

In case all 1,000,000 warrants issued within the Warrants Program 2021/2024 are utilised for subscription of new shares, a total of 1,000,000 new shares will be issued, which corresponds to a dilution of approximately 0.70 per cent of the Company’s share capital and votes after full dilution. The dilution would only have a marginal impact on the Company’s key figures ”Earnings per share” for the full year 2020.

Since previously, the Company has three outstanding warrants programs in the form of two personnel option programs, Personnel Option Program 2017/2023 I and Personnel Option Program 2017/2023 II, resolved at the annual general meeting 2017 and by the extraordinary general meeting in October 2017 (together the ”Personnel Option Programs”), and a warrants program, resolved at the annual general meeting 2020 (the ”Warrants Program 2020/2023”). The Personnel Option Programs comprise a total of 3,740,000 personnel options, whereby 4,915,108 warrants have been issued to the Subsidiary to secure delivery of shares and to secure social security contributions. Within the framework of the Warrants Program 2020/2023, a maximum of 2,800,000 warrants could be issued in accordance with the resolution of the annual general meeting. However, only 1,069,350 warrants were issued, which means that the additional maximum of 1,730,650 warrants that could be issued were never issued, nor will they be issued prior to the annual general meeting 2021. Consequently, these 1,730,650 warrants are not included in the dilution calculations below. For the avoidance of any misunderstandings, this means that the maximum dilution that may arise when exercising all warrants issued in Warrants Program 2020/2023, and proposed to be issued in Warrant Program 2021/2024, entails lower total dilution than the maximum dilution that could have occurred if all 2,800,000 warrants that could be issued in Warrant Program 2020/2023 had been issued. Each warrant in the Personnel Option Programs and the Warrants Program 2020/2023 entitle to subscription of one new share in the Company. The Personnel Option Programs lapse in August 2023 and the Warrants Program 2020/2023 lapse in September 2023.

If all of the warrants issued in the Personnel Option Programs and Warrants Program 2020/2023 are exercised for subscription of new shares, a total of 5,984,458 new shares will be issued, corresponding to a dilution of approximately 4.02 per cent of the Company’s current share capital and votes after full dilution. In case all outstanding warrants in the Personnel Option Programs, the Warrants Program 2020/2023, as well as the warrants proposed to be issued under Warrants Program 2021/2024, are utilised, a total of 6,984,458 shares will be issued, which corresponds to a dilution of approximately 4.66 per cent of the Company’s current share capital and votes after full dilution.

The above calculations regarding dilution and effect on kay ratio are subject to recalculation of the warrants in accordance with the customary recalculation terms included in the complete terms and conditions for the warrants.

The proposal of the Warrants Program 2021/2024 has been prepared by the remuneration committee together with external consultants. The final proposal has been resolved upon by the board of directors.

Item 13 – Resolution regarding authorisation of the board of directors to issue new shares
The board of directors propose that the meeting authorises the board of directors until the next annual general meeting to, on one or more occasions, resolve to increase the Company’s share capital by issue of no more than shares corresponding to ten (10) per cent of the total number of shares in the Company at the time of the meeting’s decision of authorisation.

However, such issues may not cause the share capital in the Company to exceed the Company’s highest allowed share capital according to the articles of association. The board of directors may deviate from the shareholders’ preferential rights. The reason for the board of directors’ authorisation to deviate from the shareholders’ preferential rights is to enable the Company to raise new capital and to take advantage of future opportunities to attract new long-term owners and to finance the Company’s growth strategy. The authorisation also includes the right to decide on payment for the issued shares by set-off, in kind or other conditions as referred in Chapter 13, section 5, item 6 of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)). The subscription price shall, at deviation from the shareholders’ preferential right, be determined in accordance with market practice.

Item 14 – Proposal to amend the articles of association
The board of directors of Enzymatica AB (publ) proposes that the articles of association are supplemented with terms that make it possible for the board of directors to collect power of attorneys in accordance with the procedure specified in Chapter 7, section 4, second paragraph of the Swedish Companies Act (2005:551) and that the board of directors may decide that the shareholders shall be able to exercise their voting right by post before the general meeting in accordance with the procedure specified in Chapter 7, section 4 a, of the Swedish Companies Act. The purpose of the proposal is to give the board of directors increased flexibility in the conduct of general meetings, even after the Act (2020:198) on Temporary Exemptions to Facilitate the Conduct of General Meetings has ceased to apply. Furthermore, a number of amendments due to legislative changes, as well as certain editorial amendments, are proposed. Due to the insertion of two new sections (§ 12 and § 13), it is proposed to renumber the sections, whereby the previous § 12 becomes § 14.

Current Proposed wording             
wording
§ 1. Company § 1. Business name
name The company’s business name is Enzymatica AB (publ).
The company’s
name is
Enzymatica AB
(publ).
§ 11. The § 11. The right to participate in a general meeting
right for A shareholder who wants to take part in the negotiations at a
participating general meeting shall notify the company at the latest at 4
in a general p.m. of the intention to attend no later than on the day that
meeting is set forth in the notice convening the general meeting; this
A shareholder notification shall state the number of advisors. The last
who wants to mentioned day shall not be a Sunday, other public holiday,
take part in Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve and
the shall not occur earlier than on the fifth weekday prior to the
negotiations general meeting. Proxies need not notify the number of advisors
at a general in advance. The number of advisors shall be no more than two.A
meeting shall shareholder may be accompanied by assistants at a general
notify the meeting only where the shareholder has given the company notice
company at of the number of assistants (not more than two) as specified in
the latest at the previous paragraph.
4 p.m. on the
day that is
set forth in
the notice
convening the
general
meeting; this
notification
shall state
the number of
advisors. The
last
mentioned day
shall not be
a Sunday,
other public
holiday,
Saturday,
Midsummer
Eve,
Christmas Eve
or New Year’s
Eve and shall
not occur
earlier than
on the fifth
weekday
before the
general
meeting.
Proxies need
not notify
the number of
advisors in
advance. The
number of
advisors
shall be no
more than
two.
§ 12 Collecting of powers of attorneys and vote by post
The board of directors may collect powers of attorney in
accordance with the procedure described in Chapter 7, section
4, second paragraph of the Companies Act (2005:551). The board
of directors has the right before a general meeting to decide
that shareholders shall be able to exercise their right to vote
by post before the general meeting.
§ 13 The right for persons not being shareholders to attend a
general meeting
The board of directors may resolve that persons not being
shareholders of the company shall be entitled, on the
conditions stipulated by the board of directors, to attend or
in any other manner follow the discussions at a general
meeting.

Majority rules
For a valid resolution on the proposal pursuant to item 12, the proposal has to be supported by shareholders with at least nine-tenths (9/10) of the votes cast as well as the shares represented at the meeting. For valid resolutions on the proposals pursuant to item 13 and 14, the proposals have to be supported by shareholders with at least two-thirds (2/3) of the votes cast as well as the shares represented at the meeting.

Available documents
The complete proposals and other documents that shall be made available prior to the annual general meeting pursuant to the Swedish Companies Act will be made available at the Company and on the Company’s website, www.enzymatica.se, no later than three weeks prior to the annual general meeting. The documents will also be sent free of charge to shareholders who so request and provide their address to the company. In other respects, the board of directors’ complete proposals for resolutions are stated in the notice.

Information at the annual general meeting
The board of directors and CEO shall, if any shareholder so requests and the board of directors believes that it can be done without material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda and circumstances that can affect the assessment of the Company’s or its subsidiaries’ financial situation and the Company’s relation to other companies within the group.

Request for such information shall be made in writing to the Company no later than ten (10) days prior to the annual general meeting, i.e. no later than 25 April 2021, to the address Enzymatica AB (publ), Ideon Science Park, Scheelevägen 19, 223 70 Lund (mark the envelope ”Disclosure Annual General Meeting 2021”) or by email to louise.forssell@enzymatica.com.Such a request should include the name of the shareholder including such shareholder’s personal or organisation number. It is also recommended that the submission includes the shareholder’s postal address, email address and telephone number. The information will be available on the Company’s website www.enzymatica.se and at the Company’s head office at, Ideon Science Park in Lund no later than 30 April 2021. The information will also be sent, within the same period of time, to the shareholder who has requested it and stated its address.

Shares and votes in the Company
The total number of shares and votes in the Company amounts as per the date of this notice to 142,823,696. The Company does not hold any own shares.

Processing of personal data
For information on how your personal data is processed, the Company refers to the integrity policy available on Euroclear Sweden AB’s website https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf .

____________

Lund in March 2021
Enzymatica AB (publ)
The Board of Directors

For more information please contact:
Therese Filmersson, acting CEO and CFO, Enzymatica AB
Phone: +46 (0)708-40 72 24 | Email: therese.filmersson@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases.

Enzymatica’s certified adviser is Erik Penser Bank.

Phone: +46 (0)8 463 83 00 | Email: certifiedadviser@penser.se

2021-03-29 Enzymatica Enzymatica AB: Styrelsen i Enzymatica beslutar om nyemission om 59,1 MSEK Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Enzymatica Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of SEK 59.1 million Pressreleaser Ladda ner | Visa Stäng
2021-03-23 Enzymatica Enzymatica AB: BioStock: Enzymatica om minskad försäljning och planerad nyemission Pressreleaser Visa Stäng
2021-03-22 Enzymatica Enzymatica AB: Enzymaticas försäljning och resultat påverkat av pandemin Pressreleaser Ladda ner | Visa Stäng
2021-03-22 Enzymatica Enzymatica AB: Enzymatica's sales and result affected by the pandemic Pressreleaser Ladda ner | Visa Stäng
2021-02-23 Enzymatica Enzymatica AB: BioStock: Enzymatica har bäddat för fortsatt tillväxt Pressreleaser Visa Stäng
2021-02-18 Enzymatica Enzymatica AB: BioStock Studio: Enzymaticas ordförande om framgångarna under 2020 Pressreleaser Visa Stäng
2021-02-18 Enzymatica Enzymatica AB: Positive operating result and almost doubled sales for the fourth quarter Rapporter Ladda ner | Visa Stäng
2021-02-18 Enzymatica Enzymatica AB: Positivt rörelseresultat och nästan fördubblad försäljning för det fjärde kvartalet Rapporter Ladda ner | Visa Stäng
2021-02-11 Enzymatica Enzymatica AB: Enzymatica comments on article in Dagens Medicin Pressreleaser Ladda ner | Visa Stäng
2021-02-11 Enzymatica Enzymatica AB: Enzymatica kommenterar artikel i Dagens Medicin Pressreleaser Ladda ner | Visa Stäng
2021-01-21 Enzymatica Enzymatica AB: BioStock: Enzymaticas starka tillväxt under 2020 Pressreleaser Visa Stäng
2021-01-20 Enzymatica Enzymatica AB: BioStock: Enzymatica stärker organisationen Pressreleaser Visa Stäng
2021-01-15 Enzymatica Enzymatica AB: New strategic recruitments and organizational changes at Enzymatica Pressreleaser Ladda ner | Visa Stäng
2021-01-15 Enzymatica Enzymatica AB: Nya strategiska rekryteringar och organisations-förändring hos Enzymatica Pressreleaser Ladda ner | Visa Stäng
2020-12-10 Enzymatica Enzymatica AB: BioStock: Enzymaticas avtal med STADA utökas till att inkludera Norden Pressreleaser Visa Stäng
2020-12-09 Enzymatica Enzymatica AB: STADA agreement extended for the Nordic Region Pressreleaser Ladda ner | Visa Stäng
2020-12-09 Enzymatica Enzymatica AB: STADA-avtalet utökat med Norden Pressreleaser Ladda ner | Visa Stäng
2020-11-18 Enzymatica Enzymatica AB: BioStock: Enzymatica tecknar distributionsavtal för MENA Pressreleaser Visa Stäng
2020-11-12 Enzymatica Enzymatica AB: Enzymatica ingår avtal med MS Pharma för MENA Pressreleaser Ladda ner | Visa Stäng
2020-11-12 Enzymatica Enzymatica AB: Enzymatica enters agreement with MS Pharma for MENA Pressreleaser Ladda ner | Visa Stäng
2020-11-04 Enzymatica Enzymatica AB: BioStock: Enzymaticas försäljningsutveckling fortsatte i Q3 Pressreleaser Visa Stäng
2020-11-04 Enzymatica Penser Access: Enzymatica - Positivt kassaflöde Pressreleaser Visa Stäng
2020-11-03 Enzymatica Enzymatica AB: Continued strong sales increase and positive cash flow in third quarter Rapporter Ladda ner | Visa Stäng
2020-11-03 Enzymatica Enzymatica AB: Fortsatt stark försäljningsökning samt positivt kassaflöde under det tredje kvartalet Rapporter Ladda ner | Visa Stäng
2020-10-23 Enzymatica Enzymatica AB: BioStock: Enzymatica kommenterar avtalet med Sanofi Pressreleaser Visa Stäng
2020-10-22 Enzymatica Enzymatica AB: BioStock: Enzymaticas Sanofi-avtal öppnar för försäljning av ColdZyme i Italien och Frankrike Pressreleaser Visa Stäng
2020-10-21 Enzymatica Enzymatica AB: Enzymatica ingår avtal med Sanofi gällande Frankrike och Italien för förkylningssprayen ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-10-21 Enzymatica Enzymatica AB: Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme® Pressreleaser Ladda ner | Visa Stäng
2020-10-14 Enzymatica Enzymatica AB: BioStock: Enzymatica och STADA utökar avtalet för ViruProtect Pressreleaser Visa Stäng
2020-10-13 Enzymatica Enzymatica AB: Enzymatica och STADA utökar avtalet för ViruProtect till Ryssland, Polen, Ukraina och CIS-länder Pressreleaser Ladda ner | Visa Stäng
2020-10-13 Enzymatica Enzymatica AB: Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries Pressreleaser Ladda ner | Visa Stäng
2020-10-07 Enzymatica Enzymatica AB: BioStock: Startskott för försäljning av ColdZyme i Israel Pressreleaser Visa Stäng
2020-10-07 Enzymatica Enzymatica AB: ColdZyme lanserad i Israel Pressreleaser Ladda ner | Visa Stäng
2020-10-07 Enzymatica Enzymatica AB: ColdZyme launched in Israel Pressreleaser Ladda ner | Visa Stäng
2020-09-28 Enzymatica Enzymatica AB: The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica's in vitro study on SARS-CoV-2 Pressreleaser Ladda ner | Visa Stäng
2020-09-28 Enzymatica Enzymatica AB: The Journal of Medical Virology har granskat, godkänt och publicerat resultaten från Enzymaticas in vitro-studie på SARS-CoV-2 Pressreleaser Ladda ner | Visa Stäng
2020-09-24 Enzymatica Enzymatica AB: BioStock: Enzymatica erhåller patent på två stora marknader Pressreleaser Visa Stäng
2020-09-23 Enzymatica Enzymatica AB: Nya patent godkända för ColdZyme i Japan och Ryssland Pressreleaser Ladda ner | Visa Stäng
2020-09-23 Enzymatica Enzymatica AB: New patents approved for ColdZyme in Japan and Russia Pressreleaser Ladda ner | Visa Stäng
2020-09-17 Enzymatica Enzymatica AB: Ny version - rättad den 17 september 2020 Resultaten från Enzymaticas placebokontrollerade, randomiserade studie visar statistiskt signifikant kortare förkylningar. Pressreleaser Ladda ner | Visa Stäng
2020-09-17 Enzymatica Enzymatica AB: New version - corrected 17 September, 2020 The results of Enzymatica's placebo-controlled, randomized study Pressreleaser Ladda ner | Visa Stäng
2020-08-26 Enzymatica Enzymatica AB: BioStock: Enzymaticas COO kommenterar årets framgångar Pressreleaser Visa Stäng
2020-08-17 Enzymatica Enzymatica AB: Resultaten från Enzymaticas placebokontrollerade, randomiserade studie visar statistiskt signifikant kortare förkylningar och god upplevd behandlings-effekt vid användning av ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-08-17 Enzymatica Enzymatica AB: The results of Enzymatica's placebo-controlled, randomized study show statistically significant shorter common colds and good treatment efficacy when using ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-07-20 Enzymatica Enzymatica AB: BioStock: ColdZyme kan deaktivera viruset som orsakar Covid-19 Pressreleaser Visa Stäng
2020-07-20 Enzymatica Enzymatica AB: A new in vitro study shows the ability of ColdZyme to deactivate SARS-CoV-2, the cause of the COVID-19 pandemic Pressreleaser Ladda ner | Visa Stäng
2020-07-20 Enzymatica Enzymatica AB: En ny in vitro-studie visar att ColdZyme deaktiverar SARS-Cov-2 som orsakar Covid-19 pandemin Pressreleaser Ladda ner | Visa Stäng
2020-07-17 Enzymatica Enzymatica: Penser Access: Starkt kvartal men under vår förväntan Pressreleaser Visa Stäng
2020-07-16 Enzymatica Enzymatica AB: BioStock: Nytt rekordkvartal för Enzymatica Pressreleaser Visa Stäng
2020-07-16 Enzymatica Enzymatica AB: Fördubblad försäljning även under det andra kvartalet Rapporter Ladda ner | Visa Stäng
2020-07-16 Enzymatica Enzymatica AB: Doubled sales also during the second quarter Rapporter Ladda ner | Visa Stäng
2020-06-05 Enzymatica Enzymatica AB: BioStock: Nya studiedata stärker Enzymaticas case ytterligare Pressreleaser Visa Stäng
2020-06-03 Enzymatica Enzymatica AB: Kortare förkylningar för elitidrottare med ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-06-03 Enzymatica Enzymatica AB: Shorter duration of common colds for endurance athletes with ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-05-27 Enzymatica Penser Access: Enzymatica - STADA växlar upp Pressreleaser Visa Stäng
2020-05-26 Enzymatica Enzymatica AB: BioStock: Nytt distributionsavtal mellan Enzymatica och STADA Pressreleaser Visa Stäng
2020-05-25 Enzymatica Enzymatica AB: Enzymatica och STADA utökar avtalet för Europa Pressreleaser Ladda ner | Visa Stäng
2020-05-25 Enzymatica Enzymatica AB: Enzymatica and STADA extend agreement for Europe Pressreleaser Ladda ner | Visa Stäng
2020-05-19 Enzymatica Enzymatica AB: Grant of European patent for ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-05-19 Enzymatica Enzymatica AB: Europapatent godkänt för ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-05-19 Enzymatica Enzymatica AB: BioStock: Enzymatica skyfflar om bolagsledningen Pressreleaser Visa Stäng
2020-05-18 Enzymatica Enzymatica AB: Changes in management at Enzymatica Pressreleaser Ladda ner | Visa Stäng
2020-05-18 Enzymatica Enzymatica AB: Ledningsförändringar i Enzymatica Pressreleaser Ladda ner | Visa Stäng
2020-05-06 Enzymatica Penser Access: Enzymatica - Fortsatt positiv påverkan från COVID-19 Pressreleaser Visa Stäng
2020-05-05 Enzymatica Bulletin from Annual General Meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-05 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-05 Enzymatica Enzymatica AB: BioStock: Enzymatica dubblar intäkterna i Q1 Pressreleaser Visa Stäng
2020-05-05 Enzymatica Enzymatica AB: Fördubblad försäljning och positivt resultat under det första kvartalet Rapporter Ladda ner | Visa Stäng
2020-05-05 Enzymatica Enzymatica AB: Doubled sales and positive earnings for the first quarter Rapporter Ladda ner | Visa Stäng
2020-04-27 Enzymatica Enzymatica AB: BioStock: Enzymatica erhåller den högsta EU-klassningen Pressreleaser Visa Stäng
2020-04-24 Enzymatica Enzymatica AB: ColdZyme re-certified to class III in the EU Pressreleaser Ladda ner | Visa Stäng
2020-04-24 Enzymatica Enzymatica AB: ColdZyme får klass III-godkännande inom EU Pressreleaser Ladda ner | Visa Stäng
2020-04-21 Enzymatica Enzymatica AB: Enzymatica möjliggör poströstning vid årsstämman 2020 Pressreleaser Ladda ner | Visa Stäng
2020-04-21 Enzymatica Enzymatica AB: Enzymatica enables postal voting at the Annual General Meeting 2020 Pressreleaser Ladda ner | Visa Stäng
2020-04-15 Enzymatica Penser Access: Enzymatica - COVID-19 boostar försäljningen Pressreleaser Visa Stäng
2020-04-03 Enzymatica Enzymatica AB: BioStock: Enzymatica rapporterar kraftigt ökad försäljning under 2019 Pressreleaser Visa Stäng
2020-04-03 Enzymatica Notice of annual general meeting 2020 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-04-03 Enzymatica Kallelse till årsstämma 2020 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-04-02 Enzymatica Enzymatica AB: Enzymatica - publication of the Annual Report 2019 Pressreleaser Ladda ner | Visa Stäng
2020-04-02 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2019 Pressreleaser Ladda ner | Visa Stäng
2020-03-27 Enzymatica Enzymatica AB: Enzymatica gets increased sales due to the Corona situation Pressreleaser Visa Stäng
2020-03-27 Enzymatica Enzymatica AB: Enzymatica får ökad försäljning på grund av Coronasituationen Pressreleaser Ladda ner | Visa Stäng
2020-03-24 Enzymatica Enzymatica AB: BioStock: Enzymatica äntrar den israeliska marknaden Pressreleaser Visa Stäng
2020-03-20 Enzymatica Enzymatica AB: Enzymatica tecknar avtal med Chemipal för Israel Pressreleaser Ladda ner | Visa Stäng
2020-03-20 Enzymatica Enzymatica AB: Enzymatica signs agreement with Chemipal for Israel Pressreleaser Ladda ner | Visa Stäng
2020-03-06 Enzymatica Enzymatica AB: BioStock: Användare hindrar förkylning med ColdZyme Pressreleaser Visa Stäng
2020-03-03 Enzymatica Enzymatica AB: Starka resultat från preventiv användning av ColdZyme mot förkylningsvirus Pressreleaser Ladda ner | Visa Stäng
2020-03-03 Enzymatica Enzymatica AB: Strong results from preventive use of ColdZyme against common cold virus Pressreleaser Ladda ner | Visa Stäng
2020-02-14 Enzymatica Penser Access: Enzymatica - Kosmetikaverksamheten drar upp bruttomarginalen Pressreleaser Visa Stäng
2020-02-13 Enzymatica Enzymatica AB: BioStock: Enzymatica gör sitt bästa årsresultat Pressreleaser Visa Stäng
2020-02-13 Enzymatica Enzymatica AB: ColdZyme - third largest cold brand in Sweden Rapporter Ladda ner | Visa Stäng
2020-02-13 Enzymatica Enzymatica AB: ColdZyme - tredje största varumärke i Sverige inom förkylning Rapporter Ladda ner | Visa Stäng
2020-02-03 Enzymatica Enzymatica AB: BioStock: Förlängt patentskydd för Enzymatica Pressreleaser Visa Stäng
2020-02-03 Enzymatica Enzymatica AB: The European Patent Office recommends grant of a new patent covering a key ingredient in ColdZyme against the common cold Pressreleaser Ladda ner | Visa Stäng
2020-02-03 Enzymatica Enzymatica AB: Europeiska patentverket avser att bevilja ett nytt patent för en nyckelkomponent i förkylningsprodukten ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-01-28 Enzymatica Enzymatica AB: BioStock: Avgående vd tar styrelsepost i Enzymatica Pressreleaser Visa Stäng
2020-01-28 Enzymatica Enzymatica AB: Valberedningen föreslår Fredrik Lindberg till Enzymaticas styrelse Pressreleaser Ladda ner | Visa Stäng
2020-01-28 Enzymatica Enzymatica AB: The Nomination Committee proposes that Fredrik Lindberg is elected to the Board of Directors Pressreleaser Ladda ner | Visa Stäng
2020-01-23 Enzymatica Enzymatica AB: BioStock: Enzymaticas ColdZyme lanseras i Kina via affär värd 92 Mkr Pressreleaser Visa Stäng
2020-01-22 Enzymatica Enzymatica AB: Enzymatica ingår avtal med Keyuan Trade för Kina Pressreleaser Ladda ner | Visa Stäng
2020-01-22 Enzymatica Enzymatica AB: Enzymatica signs agreement with Keyuan Trade for China Pressreleaser Ladda ner | Visa Stäng
2020-01-16 Enzymatica Enzymatica AB: BioStock: Enzymaticas ColdZyme lanseras på en första marknad i Asien Pressreleaser Visa Stäng
2020-01-14 Enzymatica Enzymatica AB: ColdZyme launched in Hong Kong Pressreleaser Ladda ner | Visa Stäng
2020-01-14 Enzymatica Enzymatica AB: ColdZyme lanserad i Hong Kong Pressreleaser Ladda ner | Visa Stäng
2020-01-10 Enzymatica Enzymatica AB: BioStock: Positiva vindar följer Enzymatica in i 2020 Pressreleaser Visa Stäng
2019-12-21 Enzymatica Enzymatica AB: Rättelse: Enzymaticas VD avgår Pressreleaser Visa Stäng
2019-12-21 Enzymatica Enzymatica AB: Enzymaticas VD avgår Pressreleaser Visa Stäng
2019-12-21 Enzymatica Enzymatica AB: Enzymatica's CEO resigns Pressreleaser Visa Stäng
2019-12-13 Enzymatica Enzymatica AB: Enzymatica in agreement for enzyme formulations for the Chinese skin care market Pressreleaser Visa Stäng
2019-12-13 Enzymatica Enzymatica AB: Enzymatica sluter avtal om leverans av enzymformuleringer för den kinesiska hudvårdsmarknaden Pressreleaser Visa Stäng
2019-11-29 Enzymatica Enzymatica AB: BioStock: Enzymaticas VD om det nya avtalet med STADA Pressreleaser Visa Stäng
2019-11-28 Enzymatica Enzymatica AB: Utökat samarbete med STADA i Tyskland Pressreleaser Ladda ner | Visa Stäng
2019-11-28 Enzymatica Enzymatica AB: STADA collaboration expands in Germany Pressreleaser Visa Stäng
2019-11-13 Enzymatica Enzymatica AB: BioStock: Bengt Baron tycker att Enzymatica är på helt rätt bana Pressreleaser Visa Stäng
2019-11-08 Enzymatica Enzymatica AB: BioStock: Enzymaticas vd nöjd med Q3-resultatet Pressreleaser Visa Stäng
2019-11-06 Enzymatica Penser Access: Enzymatica - Ny smak drar upp försäljningen Pressreleaser Visa Stäng
2019-11-05 Enzymatica Enzymatica AB: Mycket stark försäljningsökning under det tredje kvartalet Rapporter Ladda ner | Visa Stäng
2019-11-05 Enzymatica Enzymatica AB: Very strong increase of sales during the third quarter Rapporter Ladda ner | Visa Stäng
2019-10-10 Enzymatica Enzymatica AB: Enzymatica rekryterar ny kvalitetschef Pressreleaser Ladda ner | Visa Stäng
2019-10-10 Enzymatica Enzymatica AB: Enzymatica recruits new Director of Quality Assurance Pressreleaser Ladda ner | Visa Stäng
2019-09-05 Enzymatica Penser Access: Enzymatica - Negativ klinisk studie Pressreleaser Visa Stäng
2019-09-04 Enzymatica Enzymatica AB: Preliminary results of Enzymatica's placebo-controlled, randomized study did not meet the primary end-point Pressreleaser Ladda ner | Visa Stäng
2019-09-04 Enzymatica Enzymatica AB: Preliminära resultat från Enzymaticas placebokontrollerade, randomiserade studie uppfyllde inte det primära målet Pressreleaser Ladda ner | Visa Stäng
2019-08-26 Enzymatica Enzymatica AB: ColdZyme lanseras med ny smak och nya produktpåståenden Pressreleaser Visa Stäng
2019-08-26 Enzymatica Enzymatica AB: ColdZyme launches with new flavor and new product claims Pressreleaser Visa Stäng
2019-07-18 Enzymatica Penser Access: Enzymatica - Sverige visar vägen Pressreleaser Visa Stäng
2019-07-17 Enzymatica Enzymatica AB: God tillväxt under Q2, främst drivet av stark försäljning i Sverige Rapporter Ladda ner | Visa Stäng
2019-07-17 Enzymatica Enzymatica AB: Good growth in Q2, driven mainly by strong sales in Sweden Rapporter Ladda ner | Visa Stäng
2019-06-20 Enzymatica Penser Access: Enzymatica - Avtal med Maren Cosmetics Pressreleaser Visa Stäng
2019-06-19 Enzymatica Enzymatica AB: Enzymatica tecknar kosmetika-avtal till ett värde av 120 MSEK över tre år med tyska bolaget Maren Pressreleaser Ladda ner | Visa Stäng
2019-06-19 Enzymatica Enzymatica AB: Enzymatica signs supply agreement with German cosmetic company Maren, amounting to a value of SEK 120 million over a period of three years Pressreleaser Ladda ner | Visa Stäng
2019-05-08 Enzymatica Enzymatica: Penser Access: Enzymetica - Placebokontrollerad studie full rekryterad Pressreleaser Visa Stäng
2019-05-07 Enzymatica Kommuniké från årsstämma I Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-05-07 Enzymatica Bulletin from Annual General Meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-05-07 Enzymatica Enzymatica AB: Fortsatt stark tillväxt i Sverige men lägre total försäljning under kvartalet Rapporter Ladda ner | Visa Stäng
2019-05-07 Enzymatica Enzymatica AB: Continued strong growth in Sweden, but lower total sales during the quarter Rapporter Ladda ner | Visa Stäng
2019-05-03 Enzymatica Enzymatica AB: Samtliga patienter rekryterade till Enzymaticas tyska placebokontrollerade multicenterstudie med ColdZyme Pressreleaser Visa Stäng
2019-05-03 Enzymatica Enzymatica AB: All patients enrolled in Enzymatica's German placebo-controlled multicentre study with ColdZyme Pressreleaser Visa Stäng
2019-04-16 Enzymatica Enzymatica AB: Enzymatica's cold spray launched in South Africa Pressreleaser Ladda ner | Visa Stäng
2019-04-16 Enzymatica Enzymatica AB: Enzymaticas förkylningsspray lanserad i Sydafrika Pressreleaser Ladda ner | Visa Stäng
2019-04-05 Enzymatica Enzymatica AB:Kallelse till årsstämma 2019 i Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-04-05 Enzymatica Enzymatica AB:Notice of annual general meeting 2019 in Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-04-01 Enzymatica Enzymatica AB: - Publication of the annual report 2018 Pressreleaser Visa Stäng
2019-04-01 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2018 Pressreleaser Visa Stäng
2019-02-20 Enzymatica Penser Access: Enzymatica - 56% försäljningstillväxt i Sverige Pressreleaser Visa Stäng
2019-02-19 Enzymatica Enzymatica AB: Stark försäljning under fjärde kvartalet, men lägre försäljning för helåret 2018 orsakat av restriktioner i Tyskland Pressreleaser Visa Stäng
2019-02-19 Enzymatica Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany Pressreleaser Visa Stäng
2019-01-30 Enzymatica Enzymatica AB: Första patienterna inkluderade i stor placebokontrollerad multicenterstudie med ColdZyme Pressreleaser Visa Stäng
2019-01-30 Enzymatica Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme Pressreleaser Visa Stäng
2019-01-25 Enzymatica Enzymatica AB: Resultat från den tyska multicenterstudien stärker och breddar ColdZymes produktpåståenden Pressreleaser Visa Stäng
2019-01-25 Enzymatica Enzymatica AB: Results from German multicentre study strengthen and broaden ColdZyme's product claims Pressreleaser Visa Stäng
2018-12-02 Enzymatica Enzymatica AB: Enzymatica raises SEK 98.7 million in completed share issue Pressreleaser Visa Stäng
2018-12-02 Enzymatica Enzymatica AB: Enzymatica tillförs 98,7 MSEK efter avslutad nyemission Pressreleaser Visa Stäng
2018-11-12 Enzymatica Enzymatica AB: Prospekt avseende Enzymaticas företrädesemission offentliggjort Pressreleaser Visa Stäng
2018-11-12 Enzymatica Enzymatica AB: Prospectus for Enzymatica's rights issue with preferential rights for existing shareholders published Pressreleaser Visa Stäng
2018-11-05 Enzymatica Enzymatica AB: Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-11-05 Enzymatica Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-11-02 Enzymatica Enzymatica AB: Enzymatica's rights issue is secured up to 100 percent Pressreleaser Visa Stäng
2018-11-02 Enzymatica Enzymatica AB: Enzymaticas företrädesemission är säkerställd till 100 procent Pressreleaser Visa Stäng
2018-11-01 Enzymatica Penser Access: Enzymatica - Vädret & restriktioner i Tyskland dra ned försäljningen Pressreleaser Visa Stäng
2018-10-31 Enzymatica Enzymatica AB: Genombrottsavtal för Japan och lägre försäljning i Q3 på grund av restriktioner i Tyskland Pressreleaser Visa Stäng
2018-10-31 Enzymatica Enzymatica AB: Breakthrough agreement for Japan and lower sales in Q3 due to restrictions in Germany Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Kallelse till extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Notice of Extraordinary General Meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Styrelsen i Enzymatica AB beslutar om företrädesemission om 98,7 Mkr Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Enzymatica signs agreement for the Japanese market Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Enzymatica tecknar avtal för den japanska marknaden Pressreleaser Visa Stäng
2018-10-01 Enzymatica Enzymatica AB: Significant benefits from ColdZyme in a major German multicenter study evaluating different common cold symptom scales Pressreleaser Visa Stäng
2018-10-01 Enzymatica Enzymatica AB: Signifikanta fördelar med ColdZyme i en stor tysk multicenterstudie för utvärdering av olika skalor för förkylningssymptom Pressreleaser Visa Stäng
2018-08-29 Enzymatica Enzymatica AB: Appeal of court ruling on Enzymatica's cold spray in Germany Pressreleaser Visa Stäng
2018-08-29 Enzymatica Enzymatica AB: Domen mot Enzymaticas förkylningsspray i Tyskland överklagas Pressreleaser Visa Stäng
2018-07-31 Enzymatica Enzymatica AB: Enzymatica sluter avtal om ColdZyme med ABEX Pharmaceuticals för Sydafrika Pressreleaser Visa Stäng
2018-07-31 Enzymatica Enzymatica AB: Enzymatica signs agreement for ColdZyme with ABEX Pharmaceutica (Pty) Ltd for South Africa Pressreleaser Visa Stäng
2018-07-17 Enzymatica Penser Access: Enzymatica - Tidig vår förkortade förkylningssäsongen Pressreleaser Visa Stäng
2018-07-17 Enzymatica Enzymatica AB: Lägre försäljning under Q2 men 31 %-ökning för det första halvåret Pressreleaser Visa Stäng
2018-07-17 Enzymatica Enzymatica AB: Lower sales in Q2 but 31% increase for the first half of the year Pressreleaser Visa Stäng
2018-07-16 Enzymatica Enzymatica AB: Domstolsutslag lägger restriktioner på Enzymaticas förkylningsspray i Tyskland Pressreleaser Visa Stäng
2018-07-16 Enzymatica Enzymatica AB: Court ruling put restrictions on marketing of Enzymatica's cold spray in Germany Pressreleaser Visa Stäng
2018-06-07 Enzymatica Enzymatica AB: Enzymatica säkerställer finansiering av verksamheten Pressreleaser Visa Stäng
2018-06-07 Enzymatica Enzymatica AB: Enzymatica secures funding for operations Pressreleaser Visa Stäng
2018-05-22 Enzymatica Enzymatica AB: Enzymatica sluter avtal med Qualia Pharma för Grekland och Cypern Pressreleaser Visa Stäng
2018-05-22 Enzymatica Enzymatica AB: Enzymatica signs agreement with Qualia Pharma for Greece and Cyprus Pressreleaser Visa Stäng
2018-04-27 Enzymatica Penser Access: Enzymatica - STADA & svenska apotek drar upp försäljningen Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Bulletin from annual general meeting 2018 in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Kommuniké från årsstämma 2018 i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Continued growth during the first quarter Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Fortsatt tillväxt under det första kvartalet Pressreleaser Visa Stäng
2018-04-11 Enzymatica Enzymatica AB: Nya resultat från Enzymaticas in vitro-studie: ColdZyme inaktiverar även coronavirus Pressreleaser Visa Stäng
2018-04-11 Enzymatica Enzymatica AB: New results from Enzymatica's in vitro study: ColdZyme also deactivates corona virus Pressreleaser Visa Stäng
2018-04-09 Enzymatica Enzymatica AB: Ny ColdZyme-studie på elitidrottare bekräftar förebyggande och förkortande effekt Pressreleaser Visa Stäng
2018-04-09 Enzymatica Enzymatica AB: New ColdZyme study in elite athletes confirms preventive effect and reduced duration of illness Pressreleaser Visa Stäng
2018-03-28 Enzymatica Enzymatica AB: Enzymatica - publication of the annual report 2017 Pressreleaser Visa Stäng
2018-03-28 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2017 Pressreleaser Visa Stäng
2018-03-21 Enzymatica Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-03-21 Enzymatica Enzymatica AB: Kallelse till årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-02-15 Enzymatica Penser Access: Enzymatica - Uppföljningsorder från STADA drar upp försäljningen Pressreleaser Visa Stäng
2018-02-14 Enzymatica Enzymatica AB: Strong growth and international breakthrough in 2017 Pressreleaser Visa Stäng
2018-02-14 Enzymatica Enzymatica AB: Stark tillväxt och internationellt genombrott under 2017 Pressreleaser Visa Stäng
2017-11-29 Enzymatica Enzymatica AB: Enzymaticas valberedning för årsstämman 2018 utsedd Pressreleaser Visa Stäng
2017-11-29 Enzymatica Enzymatica AB: Enzymatica's Nomination Committee for the Annual General Meeting 2018 appointed Pressreleaser Visa Stäng
2017-11-14 Enzymatica Enzymatica AB: Enzymatica presenterar resultat av studie: ColdZyme har förmåga att oskadliggöra vanliga förkylningsvirus Pressreleaser Visa Stäng
2017-11-14 Enzymatica Enzymatica AB: Enzymatica announces a study showing the ability of ColdZyme to deactivate major common cold viruses Pressreleaser Visa Stäng
2017-11-09 Enzymatica Enzymatica AB: Studie om ColdZyme - Den mest rekommenderade förkylningsprodukten hos apoteken Pressreleaser Visa Stäng
2017-11-09 Enzymatica Enzymatica AB: ColdZyme study - Most recommended cold product at pharmacies Pressreleaser Visa Stäng
2017-11-02 Enzymatica Penser Access: Enzymatica - Rekordförsäljning Pressreleaser Visa Stäng
2017-11-01 Enzymatica Enzymatica AB: Delårsrapport för Enzymatica AB (publ) Januari- September 2017 Rapporter Visa Stäng
2017-11-01 Enzymatica Enzymatica AB: Interim report for Enzymatica AB (publ) January-September 2017 Pressreleaser Visa Stäng
2017-10-25 Enzymatica Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-10-25 Enzymatica Enzymatica AB: Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-10-18 Enzymatica Enzymatica AB: Fullständiga artikeln från COLDPREV I-studien publicerad - stärker dokumentation för ColdZyme Pressreleaser Visa Stäng
2017-10-18 Enzymatica Enzymatica AB: Complete article from COLDPREV I study published - strengthens documentation for ColdZyme Pressreleaser Visa Stäng
2017-09-25 Enzymatica Enzymatica AB: Kallelse till extra bolagsstämma angående bland annat personaloptionsprogram i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-09-25 Enzymatica Enzymatica AB: Notice of extraordinary general meeting regarding among other things personnel option program in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-09-06 Enzymatica Enzymatica rekryterar finanschef Pressreleaser Visa Stäng
2017-09-06 Enzymatica Enzymatica recruits Chief Financial Officer Pressreleaser Visa Stäng
2017-07-20 Enzymatica Penser Access: Enzymatica - Rekordorder från STADA Pressreleaser Visa Stäng
2017-07-20 Enzymatica Enzymatica AB: Fortsatt försäljningsökning och genombrottsorder från STADA Pressreleaser Visa Stäng
2017-07-20 Enzymatica Enzymatica AB: Continued sales growth and breakthrough order from STADA Pressreleaser Visa Stäng
2017-07-18 Enzymatica Enzymatica rekryterar Chief Commercial Officer Pressreleaser Visa Stäng
2017-07-18 Enzymatica Enzymatica recruits Chief Commercial Officer Pressreleaser Visa Stäng
2017-07-14 Enzymatica Enzymatica rekryterar Chief Operating Officer Pressreleaser Visa Stäng
2017-07-14 Enzymatica Enzymatica recruits Chief Operating Officer Pressreleaser Visa Stäng
2017-06-21 Enzymatica A study of elite athletes shows that ColdZyme provides protection as evidenced by fewer sick days and lost training days, as well as improved quality of life Pressreleaser Visa Stäng
2017-06-21 Enzymatica Studie på elitidrottare visar att ColdZyme skyddar genom att ge färre sjuk- och förlorade träningsdagar samt förbättrad livskvalitet Pressreleaser Visa Stäng
2017-06-14 Enzymatica Enzymatica får rekordorder från tyska STADA Pressreleaser Visa Stäng
2017-06-14 Enzymatica Enzymatica receives record order from STADA Arzneimittel AG Pressreleaser Visa Stäng
2017-05-23 Enzymatica Bengt Jöndell fortsätter som t f CFO Pressreleaser Visa Stäng
2017-05-23 Enzymatica Bengt Jöndell continues as acting CFO Pressreleaser Visa Stäng
2017-04-21 Enzymatica Penser Access: Enzymatica - Expansionen fortsätter i Europa Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Bulletin from annual general meeting 2017 in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Kommuniké från årsstämma 2017 i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Breakthrough in Germany and continued increase in sales Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Genombrott i Tyskland och fortsatt ökande försäljning Pressreleaser Visa Stäng
2017-04-06 Enzymatica Enzymatica AB: Enzymatica - publication of the annual report 2016 Pressreleaser Visa Stäng
2017-04-06 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2016 Pressreleaser Visa Stäng
2017-04-05 Enzymatica Enzymatica AB: Completing the Nomination Committee's in Enzymatica AB proposal for AGM 2017 regarding election of auditor Pressreleaser Ladda ner | Visa Stäng
2017-04-05 Enzymatica Enzymatica AB: Completing the Nomination Committee's in Enzymatica AB proposal for AGM 2017 regarding election of auditor Pressreleaser Visa Stäng
2017-04-05 Enzymatica Enzymatica AB: Komplettering av valberedningens i Enzymatica AB förslag inför årsstämman 2017 avseende val av revisor Pressreleaser Visa Stäng
2017-03-21 Enzymatica Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-03-21 Enzymatica Enzymatica AB: Kallelse till årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-02-21 Enzymatica Penser Access: Enzymatica - Tar klivet in i Tyskland Pressreleaser Visa Stäng
2017-02-16 Enzymatica Enzymatica AB: Geographic expansion and continued growth in 2016 Pressreleaser Visa Stäng
2017-02-16 Enzymatica Enzymatica AB:Geografisk expansion och fortsatt tillväxt under 2016 Pressreleaser Visa Stäng
2017-02-13 Enzymatica Enzymatica AB: Enzymatica ingår samarbetsavtal med STADA Arzneimittel AG Pressreleaser Visa Stäng
2017-02-13 Enzymatica Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG Pressreleaser Visa Stäng
2016-12-21 Enzymatica Enzymatica AB: Top-line results of new clinical trial Pressreleaser Ladda ner | Visa Stäng
2016-12-21 Enzymatica Enzymatica AB: Resultat från experimentell förkylningsstudie Pressreleaser Ladda ner | Visa Stäng
2016-12-19 Enzymatica Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-12-19 Enzymatica Enzymatica AB: Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (publ) Pressreleaser Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: KALLELSE TILL EXTRA BOLAGSSTÄMMA I ENZYMATICA AB (publ) Pressreleaser Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors Pressreleaser Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: Extra bolagsstämma om förändringar i styrelsen Pressreleaser Visa Stäng
2016-11-07 Enzymatica Penser Access: Enzymatica - Nya avtal på andra sidan jorden Pressreleaser Visa Stäng
2016-11-03 Enzymatica Enzymatica AB: ColdZyme® sales continue to perform well Pressreleaser Visa Stäng
2016-11-03 Enzymatica Enzymatica AB: Fortsatt god försäljningsutveckling för ColdZyme® Pressreleaser Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health Pressreleaser Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health Pressreleaser Ladda ner | Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica tecknar distributionssavtal med Endeavour Consumer Health för Australien/Nya Zeeland Pressreleaser Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica tecknar distributionssavtal med Endeavour Consumer Health för Australien/Nya Zeeland Pressreleaser Ladda ner | Visa Stäng
2016-08-30 Enzymatica Enzymatica AB: The board of directors in Enzymatica has resolved on a directed share issue of SEK 40.3 million Pressreleaser Visa Stäng
2016-08-30 Enzymatica Enzymatica AB: Styrelsen i Enzymatica beslutar om riktad nyemission om 40,3 miljoner kronor Pressreleaser Visa Stäng
2016-07-25 Enzymatica Penser Access: Enzymatica - 58% tillväxt under Q2 Pressreleaser Visa Stäng
2016-07-18 Enzymatica Enzymatica AB: Excellent volume growth for ColdZyme® Pressreleaser Visa Stäng
2016-07-18 Enzymatica Enzymatica AB: God volymutveckling för ColdZyme® Pressreleaser Visa Stäng
2016-05-25 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-05-25 Enzymatica Bulletin from the Annual General Meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-05-11 Enzymatica Enzymatica's new rights issue completed - will be provided with SEK 60 million Pressreleaser Visa Stäng
2016-05-11 Enzymatica Enzymaticas företrädesemission avslutad - tillförs 60 MSEK Pressreleaser Visa Stäng
2016-05-03 Enzymatica Enzymaticas insynspersoner avser teckna för 16 MSEK i nyemissionen Pressreleaser Visa Stäng
2016-05-03 Enzymatica Enzymatica insiders plan to subscribe for SEK 16 million in new issue Pressreleaser Visa Stäng
2016-04-26 Enzymatica Kallelse till årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-04-26 Enzymatica Notice of annual general meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-04-20 Enzymatica EP Access: Enzymatica - Nya marknader levererar Pressreleaser Visa Stäng
2016-04-20 Enzymatica Enzymatica publishes prospectus Pressreleaser Visa Stäng
2016-04-20 Enzymatica Enzymatica publicerar prospekt Pressreleaser Ladda ner | Visa Stäng
2016-04-20 Enzymatica Enzymatica publicerar årsredovisningen för 2015 Pressreleaser Visa Stäng
2016-04-20 Enzymatica Enzymatica - publication of the annual report 2015 Pressreleaser Visa Stäng
2016-04-18 Enzymatica Interim Report for Enzymatica AB (publ) January-March 2016 Rapporter Visa Stäng
2016-04-18 Enzymatica Delårsrapport för Enzymatica AB (publ) januari-mars 2016 Rapporter Visa Stäng
2016-04-14 Enzymatica Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-04-14 Enzymatica Bulletin from the extraordinary shareholders' meeting in Enzymatica Pressreleaser Visa Stäng
2016-04-01 Enzymatica Enzymatica completes acquisition of Zymetech and includes new board members and representative to the nomination committee Pressreleaser Visa Stäng
2016-04-01 Enzymatica Enzymatica slutför förvärvet av Zymetech med tillträde för nya styrelseledamöter och representant i valberedningen Pressreleaser Ladda ner | Visa Stäng
2016-03-24 Enzymatica Tillförordnad CFO för Enzymatica utsedd Pressreleaser Ladda ner | Visa Stäng
2016-03-24 Enzymatica Acting CFO of Enzymatica appointed Pressreleaser Ladda ner | Visa Stäng
2016-03-17 Enzymatica Enzymatica AB: Uppdaterad tidsplan för förvärvet av Zymetech och företrädesemissionen Pressreleaser Visa Stäng
2016-03-17 Enzymatica Enzymatica AB: Updated time plan for the acquisition of Zymetech and the rights issue Pressreleaser Visa Stäng
2016-03-15 Enzymatica Enzymatica announces new dates for its financial information Pressreleaser Visa Stäng
2016-03-15 Enzymatica Enzymatica offentliggör nya datum för den finansiella informationen Pressreleaser Visa Stäng
2016-03-15 Enzymatica Kallelse till extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-03-15 Enzymatica NOTICE OF EXTRAORDINARY SHAREHOLDERS MEETING IN ENZYMATICA AB (PUBL) Pressreleaser Visa Stäng
2016-03-15 Enzymatica Styrelsen i Enzymatica beslutar om företrädesemission om 60 miljoner SEK Pressreleaser Visa Stäng
2016-03-15 Enzymatica The board of directors in Enzymatica has resolved on a rights issue of SEK 60 million Pressreleaser Ladda ner | Visa Stäng
2016-02-18 Enzymatica Enzymatica: EP Access - Förvärvar Zymetech Pressreleaser Visa Stäng
2016-02-16 Enzymatica Enzymatica AB: Strong growth in 2015 and acquisition for international expansion Pressreleaser Ladda ner | Visa Stäng
2016-02-15 Enzymatica Bulletin from the extraordinary shareholders' meeting in Enzymatica Pressreleaser Ladda ner | Visa Stäng
2016-02-15 Enzymatica Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-02-15 Enzymatica Enzymatica AB: Stark tillväxt under 2015 och förvärv för internationell expansion Pressreleaser Visa Stäng
2016-02-03 Enzymatica Enzymatica tidigarelägger sin bokslutskommuniké 2015 Pressreleaser Ladda ner | Visa Stäng
2016-02-03 Enzymatica Enzymatica moves forward its year-end report for 2015 Pressreleaser Ladda ner | Visa Stäng
2016-01-28 Enzymatica NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (PUBL) Pressreleaser Visa Stäng
2016-01-28 Enzymatica Kallelse till extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-01-28 Enzymatica Enzymatica signs acquisition agreement and prepares for international expansion with new share issue Pressreleaser Visa Stäng
2016-01-28 Enzymatica Enzymatica ingår avtal om förvärv och förbereder internationell expansion genom nyemission Pressreleaser Ladda ner | Visa Stäng
2015-11-12 Enzymatica Enzymatica tecknar distributionssavtal med Esteve i Spanien Pressreleaser Visa Stäng
2015-11-12 Enzymatica Enzymatica signs distribution agreement with Esteve in Spain Pressreleaser Visa Stäng
2015-11-10 Enzymatica Enzymatica tecknar distributionsavtal med Tamro för den finska marknaden Pressreleaser Visa Stäng
2015-11-10 Enzymatica Enzymatica signs distribution agreement with Tamro for the Finnish market Pressreleaser Visa Stäng
2015-10-26 Enzymatica Enzymatica: EP Access - Fler kliniska studier är på gång Pressreleaser Visa Stäng
2015-10-20 Enzymatica Enzymatica AB: Delårsrapport för Enzymatica AB (publ) januari-september 2015 Rapporter Visa Stäng
2015-10-16 Enzymatica Enzymatica stärker närvaron i Storbritannien genom samarbete med apotekskedjan Lloyds Pressreleaser Visa Stäng
2015-10-16 Enzymatica Enzymatica strengthens its presence in the UK through collaboration with the Lloyds pharmacy chain Pressreleaser Visa Stäng
2015-08-04 Enzymatica Enzymatica: EP Access - Hemmamarknaden fortsätter att leverera Pressreleaser Visa Stäng
2015-07-21 Enzymatica Enzymatica: Delårsrapport för Enzymatica AB (publ) januari-juni 2015 Rapporter Visa Stäng
2015-06-15 Enzymatica Enzymatica ringde in bolaget på Nasdaq First North Pressreleaser Visa Stäng
2015-06-15 Enzymatica Enzymatica rang in the company at Nasdaq First North Pressreleaser Visa Stäng
2015-06-10 Enzymatica Enzymatica approved for listing on Nasdaq First North - trading to start June 15, 2015 Pressreleaser Ladda ner | Visa Stäng
2015-06-10 Enzymatica Enzymatica har godkänts för listning på Nasdaq First North - handelsstart den 15 juni 2015 Pressreleaser Ladda ner | Visa Stäng
2015-04-21 Enzymatica Enzymatica: Kommuniké från årsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2015-04-21 Enzymatica Enzymatica: Delårsrapport för Enzymatica AB (publ) januari-mars 2015 Pressreleaser Ladda ner | Visa Stäng
2015-04-16 Enzymatica Enzymatica: Valberedningen i Enzymatica lämnar reviderat styrelseförslag som stöds av bolagets huvudägare Pressreleaser Ladda ner | Visa Stäng
2015-04-09 Enzymatica Enzymatica: Enzymatica: Meddelande angående förslag inför årsstämma Pressreleaser Ladda ner | Visa Stäng
2015-04-08 Enzymatica Enzymatica: Valberedningens förslag till styrelse Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

16 Feb 2017 | Bokslutskommuniké 2016
20 Apr 2017 | Årsstämma 2016
21 Apr 2017 | Årligutdelning 2017
20 Jul 2017 | Kvartalsrapport 2017-Q2
1 Nov 2017 | Kvartalsrapport 2017-Q3
14 Feb 2018 | Bokslutskommuniké 2017
26 Apr 2018 | Årsstämma 2017
26 Apr 2018 | Kvartalsrapport 2018-Q1
27 Apr 2018 | Årligutdelning
17 Jul 2018 | Kvartalsrapport 2018-Q2
31 Oct 2018 | Kvartalsrapport 2018-Q3
19 Feb 2019 | Bokslutskommuniké 2018
7 May 2019 | Årsstämma 2018
7 May 2019 | Kvartalsrapport 2019-Q1
8 May 2019 | Årligutdelning
17 Jul 2019 | Kvartalsrapport 2019-Q2
13 Feb 2020 | Bokslutskommuniké 2019
5 May 2020 | Årsstämma 2019
5 May 2020 | Kvartalsrapport 2020-Q1
6 May 2020 | Årligutdelning
16 Jul 2020 | Kvartalsrapport 2020-Q2
3 Nov 2020 | Kvartalsrapport 2020-Q3
18 Feb 2021 | Bokslutskommuniké 2020
29 Apr 2021 | Kvartalsrapport 2021-Q1
5 May 2021 | Årsstämma 2020
6 May 2021 | Årligutdelning
16 Jul 2021 | Kvartalsrapport 2021-Q2
2 Nov 2021 | Kvartalsrapport 2021-Q3

ca.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner